A published patent application is a delayed window — typically around 18 months — into where a company has been putting its research dollars. The week's batch from Datadose, LLC opens that window unusually wide. The patent record shows a concentrated wave of applications, all naming the same inventor and all circling one idea: an injection device that does not just deliver a dose but reports on it.

The anchor application, US20260124401A1 ("Intelligent Injection Device for Injection Analysis and Real-Time Patient Guidance"), describes the hardware: a barrel, needle, and plunger instrumented with sensors and a microprocessor. Its abstract spells out exactly what the device is meant to measure.

The device may include a barrel in fluid communication with a needle, a piston including a plunger, a microprocessor, sensors for detecting injection parameters including: force measurement upon depression of plunger, depth measurement of needle penetration, angle measurement of the barrel relative to injection surface.— Intelligent Injection Device for Injection Analysis and Real-Time Patient Guidance, US20260124401A1

Where the filings point

What the cluster signals is not a device company so much as a data-and-services company built around a device. The surrounding applications describe layer after layer of software wrapped around that instrumented syringe. US20260124402A1 sets out an "Injectable Administration Compliance Platform" whose server receives administration data — "an injection device ID, a drug ID, a patient ID, a potency value, an administration completion flag, a timestamp, or temperature data" — and scores it against a treatment schedule. Companion filings cover the reporting module (US20260124405A1), the alerts module (US20260124403A1), and the user interface (US20260124404A1).

The filings then reach outward from the patient toward the rest of the healthcare value chain. US20260124380A1 describes a blockchain-based chain-of-custody system tracking medication "from manufacturers through distributors" to administration, and a later application, US20260144930A1 (published May 28, 2026), describes packaging aggregated administration data into "a commercial product" sold to "a pharmaceutical entity, a healthcare provider entity, a healthcare payor entity, a regulatory authority entity, or a research organization entity."

The shape of the R&D bet

By the numbers, the record holds 55 published applications assigned to Datadose, with 44 of them in the latest indexed year and nine the year before — a filing velocity that concentrates almost entirely in the recent window. The classification data underscores how single-minded the cluster is: the code G16H 20/17 (information technology for medication administration) appears on all 55 applications, and the drug-delivery code A61M 5/172 on 45 of them.

Read together, the applications point to a company quietly assembling coverage not around a molecule or a therapy but around the act of injection as a data event — capturing who administered what, when, how, and to whom, then routing that record to compliance systems, supply-chain ledgers, telemedicine portals, and, in the most recent filings, a data marketplace. The publications indicate Datadose is investing in the software, analytics, and integration scaffolding around injectable-medication administration. As applications, none of these are enforceable yet; what they show is direction, and the direction the record describes is a connected-platform play layered on top of a smart syringe.